Novartis hopes its cancer drugs drive revenues until 2030 | iPharmaCenter

Novartis has released new financial targets, forecasting annual sales growth of 5–6% at constant currencies from 2025 through 2030. This updated mid-term outlook extends the recent upward revision for 2024–2029, now set at a 6% constant currency compound annual growth rate (CAGR).

The company anticipates growth in its oncology business to play a key role in driving revenue.

Novartis has lifted the peak sales projections for its cancer therapies Kisqali and Scemblix, with the expected peak for Kisqali climbing to $10 billion, and Scemblix to $4 billion.

Cosentyx is expected to generate $8 billion before LoE, Kesimpta has potential to generate $6 billion, and radioligand therapy Pluvicto is expected to generate $5 billion revenues.

These drugs are now part of a portfolio of eight marketed, lower-risk assets that together hold the potential to deliver between $3 billion and $10 billion each in peak yearly sales.

Between 2025 and 2030, key products fueling revenue growth are set to include Kisqali, Leqvio, Kesimpta, Fabhalta, Scemblix, Vanrafia, Pluvicto, Rhapsido, ianalumab, pelacarsen, Ac-PSMA-617, OAV101 IT, and del-desiran.

On the horizon, several established brands such as Entresto, Jakavi, Promacta, Cosentyx, Xolair, Tasigna, and Sandostatin LAR are expected to face generic competition before the decade ends.

Novartis growth drivers and best selling drugs